CONTEXT: Intratumour heterogeneity (ITH) can impair the precise molecular analysis of tumours and may contribute to difficulties encountered in cancer biomarker qualification and treatment personalisation.
OBJECTIVE: This review summarises the evidence for genetic ITH in renal, bladder, and prostate carcinomas and potential strategies to address the clinical and translational research challenges arising from ITH.
EVIDENCE ACQUISITION: Publications that assessed ITH in the relevant urologic cancers were identified in a literature review.
EVIDENCE SYNTHESIS: ITH with functionally distinct tumour subclones has been identified in all three tumour types. Heterogeneity of actionable genetic changes and of prognostic biomarkers between different tumour regions in the same patient suggests limitations of single biopsy-based molecular analyses for precision medicine approaches. Evolutionary constraints may differ between patients and may allow the prediction of specific evolutionary trajectories.
CONCLUSIONS: Assessment of multiple tumour regions for precision medicine purposes, monitoring of subclonal dynamics over time, and the preferential targeting of genetic alterations located on the trunk of the phylogenetic tree of individual cancers may accelerate the development of personalised medicine strategies and improve our understanding of treatment failure.
PATIENT SUMMARY: Genetic alterations can be heterogeneous within urologic tumours, complicating their use as biomarkers for treatment personalisation. We present novel strategies to address these challenges.
Written by:
Gerlinger M, Catto JW, Orntoft TF, Real FX, Zwarthoff EC, Swanton C. Are you the author?
Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK; The Royal Marsden Hospital, London, UK; Academic Urology Unit, University of Sheffield, Sheffield, South Yorkshire, UK; Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Epithelial Carcinogenesis Group, Molecular Pathology Program, CNIO (Spanish National Cancer Research Centre), Madrid, Spain; Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain; Department of Pathology, Erasmus MC, Rotterdam, The Netherlands; CR-UK London Research Institute, London, UK; University College London Cancer Institute, London, UK. ;
Reference: Eur Urol. 2014 May 2. pii: S0302-2838(14)00395-9.
doi: 10.1016/j.eururo.2014.04.014
PubMed Abstract
PMID: 24836153
UroToday.com Renal Cancer Section
